Tiziana Life Sciences company info

What does Tiziana Life Sciences do?
Tiziana Life Sciences (NASDAQ:TLSA) is a biotechnology firm dedicated to discovering and developing novel therapies that can potentially transform the treatment of diseases in fields such as immunology and oncology. At the heart of its operations are projects targeting the modulation of the human immune system, aiming at diseases that currently have limited treatment options. Their objectives include advancing their pipeline of therapeutic candidates through clinical trials with the ultimate goal of bringing transformative treatments to market. The company's research focuses on leveraging its expertise in monoclonal antibodies and small molecules to potentially improve patient outcomes in areas such as multiple sclerosis, Crohn's disease, and cancer.
Tiziana Life Sciences company media
Company Snapshot

Is Tiziana Life Sciences a public or private company?

key
Ownership
Public

How many people does Tiziana Life Sciences employ?

people
Employees
7

What sector is Tiziana Life Sciences in?

pie chart
Sector
Health Care

Where is the head office for Tiziana Life Sciences?

location pin
Head Office
London, United Kingdom

What year was Tiziana Life Sciences founded?

founded flag
Year Founded
1998
What does Tiziana Life Sciences specialise in?
/Biopharmaceutical Company /Immunotherapy Research /Innovative Medicine /Cancer Treatments /Multiple Sclerosis Therapy /COVID-19 Treatment

What are the products and/or services of Tiziana Life Sciences?

Overview of Tiziana Life Sciences offerings
Anti-Claudin 18.2 (TCN): Their lead drug candidate targeting Claudin 18.2 expressing tumors, which are found in various cancers including gastric, esophageal, pancreatic, and non-small cell lung cancer.
Anti-CD38 (TSL-272): This drug candidate targets CD38, a protein expressed on the surface of multiple myeloma and other hematological malignancies.
Anti-EphA2 (TSL-118): This drug candidate targets EphA2, a receptor tyrosine kinase overexpressed in several solid tumors.
Anti-Fc?RIIb (TSL-132): This drug candidate targets Fc?RIIb, an inhibitory receptor on macrophages that can be exploited to enhance antibody-dependent cellular cytotoxicity (ADCC) of therapeutic antibodies.
Discovery and Development Efforts: Tiziana Life Sciences has a pipeline of other discovery and development efforts targeting various diseases.
Collaboration Partnerships: They partner with other biotechnology and pharmaceutical companies to leverage their expertise and resources.

Who is in the executive team of Tiziana Life Sciences?

Tiziana Life Sciences leadership team
  • Mr. Gabriele Marco Antonio Cerrone M.B.A.
    Mr. Gabriele Marco Antonio Cerrone M.B.A.
    Founder, Executive Chairman & Interim CEO
  • Dr. Andrea  Brancale
    Dr. Andrea Brancale
    Scientific Founder
  • Mr. Richard  Clarkson Ph.D.
    Mr. Richard Clarkson Ph.D.
    Scientific Founder
  • Mr. Andrew  Westwell Ph.D.
    Mr. Andrew Westwell Ph.D.
    Scientific Founder
  • Ms. Keeren  Shah
    Ms. Keeren Shah
    Chief Financial Officer
  • Dr. Matthew W. Davis M.D., R.Ph.
    Dr. Matthew W. Davis M.D., R.Ph.
    COO & Chief Medical Officer
  • Dr. William A. Clementi Ph.D., Pharm.D.
    Dr. William A. Clementi Ph.D., Pharm.D.
    Chief Development Officer
  • Dr. Napoleone  Ferrara M.D.
    Dr. Napoleone Ferrara M.D.
    Member of Scientific Advisory Board